江苏蓝丰生物化工股份有限公司 2025年度业绩预告

Group 1 - The company expects a negative net profit for the fiscal year 2025, indicating financial challenges ahead [2][3] - The company plans to recognize asset impairment losses totaling approximately 86.76 million yuan, which will reduce the net profit attributable to shareholders by about 64.16 million yuan [3][11] - The impairment preparation includes various asset categories such as accounts receivable, inventory, and fixed assets, reflecting a cautious approach to financial reporting [7][11] Group 2 - The company has communicated with its auditing firm regarding the preliminary estimates for the performance forecast, with no significant disagreements noted [2][3] - The decline in profitability is attributed to rising raw material costs and decreasing sales prices in the agricultural chemical sector, alongside competitive pressures in the renewable energy sector [3][11] - The company has conducted a comprehensive review of its assets to identify impairment signs, adhering to prudent accounting principles [7][11]